請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7984
標題: | 以碳青黴烯類的細菌治療多重抗性來評估抗生素的全球市場 Evaluating the global antibiotic market from a unique presepective of multidrug resistant bacterial infection with a focus on the carbapenems |
作者: | Wei-Jen Chen 陳薇任 |
指導教授: | 李財坤(Tsai-Kun Li) |
關鍵字: | 抗生素抗藥性,抗生素市場,碳青黴烯類,培南類抗生素,美洛培南,亞胺培南/西司他丁,厄它培南, antibiotic resistance,antibiotic market,carbapenems,peinan antibiotics,Meropenem,Imipenem/Cilastatin,Ertapenem, |
出版年 : | 2019 |
學位: | 碩士 |
摘要: | 本研究以抗生素的最後一道防線”碳青黴烯類(Cabapenems)”為主,來探討細菌治療多重抗性的發展,用以評估抗生素全球市場。由於Carbapenems抗生素,是屬於嚴重感染症的後線用藥,探討目的是要分析抗生素後線用藥在抗藥性日趨嚴重下,對抗生素市場是否有相關變化。
依IMS 數據分析目前上市之Carbapenems抗生素做2017年與2018年全球銷售額、消耗量統計及成長率分析,包含:美洛培南(Meropenem )、亞胺培南/西司他丁(Imipenem/Cilastatin )、厄它培南(Ertapenem)、多利培南(Doripenem)、法羅培南(Faropenem)、替比培南(Tebipenem)及比阿培南(Biapenem)等七種。其中未包含複方的帕尼培南/倍他米隆(Panipenem/ Betamipron),由於市場長期低迷,將不進行討論。整體而言,若以2017~2018年Carbapenems抗生素全球消耗量不分區域來看,總體消耗量下降6.7%,顯示全球已開發國家都已建立控管機制,已具有些許成效。 再以Carbapenems中市佔率第一的Meropenem來進行全球2015~2018年各區域的銷售額vs.消耗量相關性分析,藉以了解全球各區域市場銷售額與消耗量之相關性與差異。分析後發現,Carbapenems銷售額與消耗量之關係,取決於政府對藥價的定價方式,以美國及拉丁美洲來看,則無法從市場(銷售額)看出抗生素使用量關係,而歐洲、全球其他國家及台灣則呈現市場(銷售額)與抗生素使用量趨勢高度相關的結果。 台灣由2017年抗生素抗藥性監管成效來看,2008~2017年除了MRSA趨勢下降外,其他感染菌種皆持續上升中,與台灣Carbapenems抗生素消耗連續3年呈現大幅上升趨勢情況一致,顯見台灣抗生素抗藥性問題日趨嚴重。 如何抵抗超級細菌的威脅,是全球的重要課題,需要各國政府的積極政策推動。“推動的首要關鍵是,在患者剛剛輕微感染的第一個跡象下,獲得處方的權利將是全球抵抗抗藥性的推動者”。因此,需要更積極的開發國際運動與呼籲來教育醫療保健提供者,患者和非專業人員,以限制人類、農業及畜牧業中抗生素的過度使用和濫用。 In this study, the last line of antibiotics, 'Cabapenems', was used to explore the development of multi-resistance in bacterial treatment to assess the global market for antibiotics. Because Carbapenems antibiotics are a late-line medication for serious infections, the purpose of the study is to analyze whether there is a relevant change in the antibiotic market under the increasing drug resistance of antibiotics. According to IMS data, the current markets Carbapenems antibiotics will be analyzed for global sales and consumption in 2017 and 2018, and growth rates from 2017 to 2018, including seven species: Meropenem, Imipenem/Cilastatin, Ertapenem, Doripenem, Faropenem, Tebipenem, and Biapenem. Panipenem/Betamipron, which does not contain the compound, will not be discussed due to the long-term downturn in the market. Overall, if the global consumption of Carbapenems antibiotics is not divided into regions in 2017~2018, the overall consumption was decreased by 6.7%, indicating that the developed countries have established control antibiotic resistance and have some success results. Based on Meropenem, the market share of Carbapenems, the correlation analysis of sales and consumption in various regions in the global from 2015 to 2018 was conducted to understand the correlation between the market and antibiotic resistance. After analysis, it is found that the relationship between sales and consumption of Carbapenems depends on the government's pricing method for drug prices. In the United States and Latin America, the relationship between antibiotic usage cannot be seen from the market (sales), while Europe and the world other countries and Taiwan have shown a high correlation between market (sales) and antibiotic using trends. Taiwan's 2017 antibiotic resistance surveillance control effect, in addition to the decline in MRSA trends in 2008~2017, other infectious strains continue to rise, consistent with the situation that Taiwan's Carbapenems antibiotic consumption has shown a sharp upward trend for three consecutive years. It is obvious that the problem of antibiotic resistance in Taiwan is becoming more and more serious. How to resist the threat of super bacteria is an important issue in the global and requires the active policy promotion of governments. “The first key to the push is that under the first trace of a patient's initial mild infection, the right to get a prescription will be the promoter for Global resistance to drug resistance.”Therefore, there is a need for more active development of international campaigns and appeals to educate health care providers, patients and non-professionals to limit the excessive use and abuse of antibiotics in human, agricultural and livestock industries. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7984 |
DOI: | 10.6342/NTU201903938 |
全文授權: | 同意授權(全球公開) |
顯示於系所單位: | 生物科技管理碩士在職學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf | 4.75 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。